Ziconotide

Identification

Name
Ziconotide
Accession Number
DB06283
Type
Small Molecule
Groups
Approved
Description

Ziconotide (SNX-111; Prialt) is an atypical analgesic agent for the amelioration of severe and chronic pain. Derived from Conus magus (Cone Snail), it is the synthetic form of an ω-conotoxin peptide. In December 2004 the Food and Drug Administration approved ziconotide when delivered as an infusion into the cerebrospinal fluid using an intrathecal pump system.

Structure
Thumb
Synonyms
Not Available
External IDs
SNX-111
Product Ingredients
IngredientUNIICASInChI Key
Ziconotide acetateT2I226K69M914454-03-8Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PrialtInjection, solution100 ug/mLIntrathecalJazz Pharmaceuticals2004-12-28Not applicableUs
PrialtInjection, solution100 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution25 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution100 ug/mLIntrathecalJazz Pharmaceuticals2004-12-28Not applicableUs
PrialtInjection, solution100 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution25 ug/mLIntrathecalJazz Pharmaceuticals2004-12-28Not applicableUs
PrialtInjection, solution100 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
Categories
UNII
7I64C51O16
CAS number
107452-89-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Ziconotide is a hydrophilic molecule that is freely soluble in water and is practically insoluble in methyl t-butyl ether. Ziconotide acts as a selective N-type voltage-gated calcium channel blocker. This action inhibits the release of pro-nociceptive neurochemicals like glutamate, calcitonin gene-related peptide (CGRP), and substance P in the brain and spinal cord, resulting in pain relief.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Ziconotide.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Ziconotide.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ziconotide.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ziconotide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ziconotide.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Ziconotide.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ziconotide.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ziconotide.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ziconotide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Ziconotide.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Ziconotide.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ziconotide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Ziconotide.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ziconotide.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ziconotide.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ziconotide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ziconotide.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Ziconotide.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ziconotide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ziconotide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ziconotide.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Ziconotide.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ziconotide.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Ziconotide.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Ziconotide.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ziconotide.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Ziconotide is combined with Atosiban.Approved
Atracurium besylateZiconotide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Ziconotide.Vet Approved
AzelastineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ziconotide.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Ziconotide.Experimental
BarbexacloneThe metabolism of Ziconotide can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ziconotide.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Ziconotide.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ziconotide.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Ziconotide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ziconotide.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Ziconotide.Approved
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Ziconotide.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ziconotide is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ziconotide.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Ziconotide.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Ziconotide.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ziconotide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Ziconotide.Approved, Withdrawn
BucindololBucindolol may increase the hypotensive activities of Ziconotide.Investigational
BunazosinBunazosin may increase the hypotensive activities of Ziconotide.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ziconotide.Approved, Investigational
BuprenorphineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ziconotide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ziconotide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Ziconotide.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ziconotide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Ziconotide.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Ziconotide.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ziconotide.Approved, Illicit
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Ziconotide.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ziconotide.Approved, Illicit, Vet Approved
CalciumThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Carbonate.Approved
Calcium CitrateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium lactate.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Ziconotide.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Ziconotide.Investigational
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Ziconotide.Experimental
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ziconotide.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ziconotide.Approved
CarbomycinThe metabolism of Ziconotide can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ziconotide.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ziconotide.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Ziconotide.Approved, Investigational
CaseinThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Ziconotide.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Ziconotide.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ziconotide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ziconotide.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ziconotide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ziconotide.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ziconotide.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Ziconotide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ziconotide.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ziconotide.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ziconotide.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ziconotide.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Ziconotide.Approved, Investigational
CimetidineThe serum concentration of Ziconotide can be increased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ziconotide.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ziconotide is combined with Citalopram.Approved
ClarithromycinThe metabolism of Ziconotide can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ziconotide.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Ziconotide.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ziconotide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ziconotide.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ziconotide.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Ziconotide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ziconotide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Ziconotide.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ziconotide.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ziconotide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Ziconotide.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Ziconotide.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ziconotide.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ziconotide.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ziconotide.Approved, Illicit
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Ziconotide.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Ziconotide.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziconotide.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ziconotide.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ziconotide.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ziconotide.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ziconotide.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Ziconotide.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Ziconotide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ziconotide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ziconotide.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ziconotide.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Ziconotide.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ziconotide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ziconotide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ziconotide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ziconotide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ziconotide.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ziconotide.Approved, Illicit, Vet Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Ziconotide.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Ziconotide.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Ziconotide.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ziconotide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ziconotide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ziconotide.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ziconotide.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ziconotide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ziconotide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Ziconotide.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Ziconotide.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Ziconotide.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ziconotide.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Ziconotide.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ziconotide.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ziconotide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ziconotide.Experimental, Illicit
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Ziconotide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ziconotide.Investigational
EfavirenzThe serum concentration of Ziconotide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Ziconotide.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Ziconotide.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ziconotide.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ziconotide.Approved, Investigational
ErythromycinThe metabolism of Ziconotide can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ziconotide is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ziconotide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ziconotide.Approved
EthanolZiconotide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziconotide.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ziconotide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ziconotide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ziconotide.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Ziconotide.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ziconotide.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ziconotide.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Ziconotide.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Ziconotide.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Ziconotide.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ziconotide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ziconotide.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Ziconotide.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Ziconotide.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ziconotide.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ziconotide.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Ziconotide.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Ziconotide.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ziconotide.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Ziconotide.Experimental
FluconazoleThe serum concentration of Ziconotide can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Ziconotide.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ziconotide.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ziconotide.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ziconotide.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ziconotide.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ziconotide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ziconotide.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ziconotide.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ziconotide.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Ziconotide.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ziconotide.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Ziconotide.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ziconotide.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ziconotide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ziconotide is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ziconotide.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Ziconotide.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ziconotide.Approved, Illicit
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Ziconotide.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Ziconotide.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ziconotide.Approved, Investigational
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Ziconotide.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ziconotide.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ziconotide.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Ziconotide.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ziconotide.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ziconotide.Approved, Illicit
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Ziconotide.Approved
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ziconotide.Approved
HydrocodoneZiconotide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziconotide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ziconotide.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ziconotide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Ziconotide.Investigational
IndoraminIndoramin may increase the hypotensive activities of Ziconotide.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Ziconotide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ziconotide.Approved, Vet Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Ziconotide.Approved, Investigational
JosamycinThe metabolism of Ziconotide can be decreased when combined with Josamycin.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ziconotide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ziconotide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ziconotide.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Ziconotide.Approved, Investigational
KitasamycinThe metabolism of Ziconotide can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Ziconotide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ziconotide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ziconotide.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ziconotide.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ziconotide.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Ziconotide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ziconotide.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ziconotide is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ziconotide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ziconotide.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ziconotide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Ziconotide.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Ziconotide.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ziconotide.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ziconotide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Ziconotide.Approved
LovastatinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ziconotide.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ziconotide.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ziconotide.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Ziconotide.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ziconotide.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Ziconotide.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Ziconotide.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ziconotide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Ziconotide.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Ziconotide.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ziconotide.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ziconotide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Ziconotide.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ziconotide.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ziconotide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ziconotide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ziconotide.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ziconotide.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ziconotide.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ziconotide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ziconotide.Approved
MethotrimeprazineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ziconotide.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ziconotide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ziconotide.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ziconotide.Approved
MetyrosineZiconotide may increase the sedative activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Ziconotide.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Ziconotide.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Ziconotide.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ziconotide.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Ziconotide is combined with Milnacipran.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Ziconotide.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Investigational
MirtazapineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumZiconotide may increase the neuromuscular blocking activities of Mivacurium.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ziconotide.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Ziconotide.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ziconotide.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Ziconotide.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved, Investigational
NafcillinThe metabolism of Ziconotide can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Ziconotide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ziconotide.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Ziconotide.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Nefazodone.Approved, Withdrawn
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Ziconotide.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Ziconotide.Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ziconotide.Approved
NitroprussideZiconotide may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ziconotide.Approved, Vet Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Ziconotide.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Ziconotide.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Ziconotide.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ziconotide.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Ziconotide.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ziconotide.Approved, Investigational
OleandomycinThe metabolism of Ziconotide can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ziconotide.Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Ziconotide.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ziconotide.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Ziconotide.Approved, Illicit
OrphenadrineZiconotide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ziconotide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ziconotide.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Ziconotide.Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Ziconotide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ziconotide.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ziconotide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ziconotide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ziconotide.Approved, Investigational, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Ziconotide.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ziconotide.Approved
ParaldehydeZiconotide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Ziconotide.Experimental
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Ziconotide.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ziconotide.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ziconotide.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Ziconotide.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Ziconotide.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ziconotide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ziconotide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Ziconotide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Ziconotide.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ziconotide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Ziconotide.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ziconotide.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ziconotide.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ziconotide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ziconotide.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ziconotide.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Ziconotide.Investigational
PitavastatinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pitavastatin.Approved
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Ziconotide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Ziconotide.Approved, Investigational, Vet Approved
PramipexoleZiconotide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ziconotide.Approved
PravastatinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ziconotide.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Ziconotide.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ziconotide.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ziconotide.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Ziconotide.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ziconotide.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ziconotide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ziconotide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ziconotide.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Ziconotide.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ziconotide.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ziconotide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Ziconotide.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ziconotide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Ziconotide.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ziconotide.Investigational
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Ziconotide.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ziconotide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ziconotide.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Ziconotide.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Ziconotide.Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Ziconotide.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ziconotide.Approved, Investigational
RapacuroniumZiconotide may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ziconotide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ziconotide.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ziconotide.Approved
RifabutinThe serum concentration of Ziconotide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ziconotide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ziconotide can be decreased when it is combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ziconotide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Ziconotide.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Ziconotide.Vet Approved
RopiniroleZiconotide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ziconotide.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Rosuvastatin.Approved
RotigotineZiconotide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ziconotide.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Ziconotide.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ziconotide.Approved, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ziconotide.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ziconotide.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Ziconotide.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Ziconotide.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ziconotide.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ziconotide.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Ziconotide.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Ziconotide is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Ziconotide.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Ziconotide.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
SolithromycinThe metabolism of Ziconotide can be decreased when combined with Solithromycin.Investigational
StiripentolThe risk or severity of adverse effects can be increased when Ziconotide is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Ziconotide.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ziconotide.Approved
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Ziconotide.Experimental
SuvorexantZiconotide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Ziconotide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Ziconotide.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tasimelteon.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Ziconotide.Approved
TelithromycinThe metabolism of Ziconotide can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ziconotide.Approved
TerazosinTerazosin may increase the hypotensive activities of Ziconotide.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Ziconotide.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Ziconotide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziconotide.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ziconotide.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ziconotide.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ziconotide.Investigational
ThalidomideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ziconotide.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ziconotide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ziconotide.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ziconotide.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Ziconotide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ziconotide.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Ziconotide.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Ziconotide.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Ziconotide.Experimental
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Ziconotide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ziconotide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ziconotide.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Ziconotide.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Ziconotide.Approved, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ziconotide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ziconotide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ziconotide.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziconotide.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ziconotide.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ziconotide.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Ziconotide.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Ziconotide.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ziconotide.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Ziconotide.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ziconotide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Ziconotide.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Ziconotide.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziconotide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ziconotide.Approved
TylosinThe metabolism of Ziconotide can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ubidecarenone.Experimental
UrapidilUrapidil may increase the hypotensive activities of Ziconotide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ziconotide.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Ziconotide.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Ziconotide.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Ziconotide.Experimental
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Ziconotide.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ziconotide.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Ziconotide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Ziconotide.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ziconotide.Approved, Illicit, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Ziconotide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ziconotide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Ziconotide.Vet Approved
ZolpidemZiconotide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ziconotide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ziconotide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Ziconotide.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ziconotide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Skov MJ, Beck JC, de Kater AW, Shopp GM: Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol. 2007 Sep-Oct;26(5):411-21. [PubMed:17963128]
  2. McIntosh M, Cruz LJ, Hunkapiller MW, Gray WR, Olivera BM: Isolation and structure of a peptide toxin from the marine snail Conus magus. Arch Biochem Biophys. 1982 Oct 1;218(1):329-34. [PubMed:7149738]
  3. Miljanich GP: Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004 Dec;11(23):3029-40. [PubMed:15578997]
  4. McGivern JG: Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat. 2007 Feb;3(1):69-85. [PubMed:19300539]
External Links
KEGG Drug
D06363
ChEMBL
CHEMBL2103752
Wikipedia
Ziconotide
ATC Codes
N02BG08 — Ziconotide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentCancers / Pain / Pain, Intractable / Pain, Neuropathic1
2CompletedTreatmentCancers / Human Immunodeficiency Virus (HIV) Infections / Pain1
3CompletedTreatmentPain2
4CompletedNot AvailablePeripheral Neuropathy1
4WithdrawnTreatmentPainful Myelopathy / Painful Neuropathy1
Not AvailableCompletedNot AvailablePatients With Severe Chronic Pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntrathecal100 ug/mL
Injection, solutionIntrathecal100 μg/ml
Injection, solutionIntrathecal25 μg/ml
Injection, solutionIntrathecal25 ug/mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5859186No1994-12-302011-12-30Us
US5364842No1996-12-302016-12-30Us
US8653033No2004-10-012024-10-01Us
US8765680No2004-10-012024-10-01Us
US9707270No2004-10-012024-10-01Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:21 / Updated on August 08, 2017 04:48